Buy & Sell Cardinal Health Inc (CAH) – Cardinal Health Inc Price Today
Aura AI Summary
Key Stats
- $47.00BMarket Cap
- HealthSector
- -20.61%3M Drawdown
- $51.98BEnterprise Value
- 1.02%Dividend Yield
- 66 daysTypical Hold Time
Cardinal Health Inc (CAH) is currently valued at a market capitalization of $47.00B, with an enterprise value of $51.98B. Over the past 52 weeks, Cardinal Health Inc has traded between a low of $146.04 and a high of $229.88, highlighting its annual price range. Over the past three months, Cardinal Health Inc has recorded a drawdown of -20.61%, reflecting recent price volatility. Cardinal Health Inc offers a dividend yield of 1.02%, with the most recent dividend of $0.51 paid on 01 Apr 26. On average, investors hold Cardinal Health Inc for approximately 66 days, indicating typical investor behavior on the platform.
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Most Recent News
Investigation launched over Regeneron’s optimistic trial claims that preceded stock drop.
Levi & Korsinsky has started an investigation into Regeneron Pharmaceuticals for potentially misleading investors about the results of a clinical trial. In March 2026, Regeneron's investor relations VP expressed hope for positive trial outcomes of a ...

Investigation launched into Prestige Consumer Healthcare over missed earnings and undisclosed acquisition
Levi & Korsinsky has started an investigation into Prestige Consumer Healthcare following the company's failure to meet its Q4 and full-year financial projections, including adjusted gross margin, free cash flow, and adjusted EPS. Additionally, Prest...

Investigation launched into TriSalus Life Sciences after Q1 revenue misses estimates and cuts full-year guidance
Levi & Korsinsky has started an investigation into TriSalus Life Sciences following the company's Q1 2026 revenue of $8.9 million, which missed Wall Street's $9.4 million estimate. The company also lowered its full-year 2026 revenue forecast to $54 m...
